J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Puma Biotechnology (NYSEArca: PBYI) today and set a price target of $83. The company’s shares closed yesterday at $48.65, close to its 52-week low of $46.55.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.7% and a 41.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Jounce Therapeutics Inc.
Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $83.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $136.90 and a one-year low of $46.55. Currently, Puma Biotechnology has an average volume of 927.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.
